|
|
Volumn 9, Issue 2, 2010, Pages 94-
|
|
Deal watch: Celgene acquires Gloucester pharmaceuticals, gaining approved HDAC inhibitor.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC ANTIBIOTIC;
DEPSIPEPTIDE;
HISTONE DEACETYLASE INHIBITOR;
ROMIDEPSIN;
CUTANEOUS T CELL LYMPHOMA;
DRUG APPROVAL;
DRUG INDUSTRY;
ECONOMICS;
HUMAN;
NOTE;
PATHOPHYSIOLOGY;
SKIN TUMOR;
ANTIBIOTICS, ANTINEOPLASTIC;
DEPSIPEPTIDES;
DRUG APPROVAL;
DRUG INDUSTRY;
HISTONE DEACETYLASE INHIBITORS;
HUMANS;
LYMPHOMA, T-CELL, CUTANEOUS;
SKIN NEOPLASMS;
|
|
EID: 77449093694
PISSN: None
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3112 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|